alexa Editor - Cynthia Xiuguang Ma | Washington University School of M | 18581
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Relevant Topics

Cynthia Xiuguang Ma

Cynthia Xiuguang Ma
Cynthia Xiuguang Ma
Associate Professor
Division of Oncology
Washington University School of Medicine
USA
Tel: 314-362-9383
Fax: 314-362-7086
Washington University School of Medicine

Biography

Dr. Cynthia Ma obtained her MD from Beijing Medical University in China and subsequently PhD in Developmental Biology from the University of Cincinnati. She completed her Internal Medicine residency from New Hanover Regional Medical Center in North Carolina followed by the Hematology/Medical Oncology fellowship at Mayo Clinic, Rochester, Minnesota. In 2005, she was recruited as a breast oncologist at Washington University School of Medicine (WUSM). She is currently an Associate Professor of Medicine and a research member of Siteman Cancer Center. In August 2014, Dr. Ma was appointed as the Clinical Director of the Breast Cancer Program, Section of Medical Oncology, Division of Oncology at WUSM. Dr. Ma’s research includes preclinical and clinical trial development of molecularly targeted cancer therapeutics for the treatment of resistant breast cancer. She is the principal investigator for several biomarker directed clinical trials of biological agents including UCN-01, temsirolimus, MK2206, BKM120, IMC-A12, and palbociclib in breast cancer.

Research Interest

Identification of predictive genetic markers in the treatment of breast cancer, especially with hormonal and other targeted therapies, pharmacogenomics, phase I and II clinical trials to develop novel therapeutic agents for the treatment of solid tumors, especially breast cancer

Certificate

Certificate

Global Speakers in the subject

Global Experts in the subject

Leave Your Message 24x7
Top